MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie 
Welcome,         Profile    Billing    Logout  
 6 Diseases   0 Trials   0 Trials   78 News 
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie
    Restrictive Domains in Healthcare Opioid Legislation in Low- and Middle-Income Countries (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_1524;    
    While analyses of associations of restrictive domains and HDI and QDI are ongoing and results are pending, this scoping review preliminarily calls attention to the specific restrictive domains of the legislative language that may negatively influence access to quality pain management.Individual models of success in facilitating access to opioids and developing palliative care programs were identified in Nepal, Mongolia, and Uganda.
  • ||||||||||  Nucynta (tapentadol) / Collegium Pharma, Grunenthal
    Journal:  Prescribing Trend of Tapentadol in a Sydney Local Health District. (Pubmed Central) -  Aug 22, 2022   
    In a Sydney LHD, tapentadol prescriptions increased significantly to become the preferred opioid analgesic. At the hospital's surgical units, off-label prescriptions of tapentadol sustained-release for acute post-operative pain were observed.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie
    Review, Journal:  Oxycodone for cancer-related pain. (Pubmed Central) -  Jun 19, 2022   
    Our conclusions are consistent with other reviews and suggest that, while the reliability of the evidence base is low, given the absence of important differences within this analysis, it seems unlikely that larger head-to-head studies of oxycodone versus morphine are justified, although well-designed trials comparing oxycodone to other strong analgesics may well be useful. For clinical purposes, oxycodone or morphine can be used as first-line oral opioids for relief of cancer pain in adults.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, Arymo (morphine) / Assertio
    Journal:  Association of partial systemic exposure and abuse potential for opioid analgesics with abuse deterrence labeling claims supporting product-specific guidance. (Pubmed Central) -  Sep 30, 2021   
    Extensive pharmacokinetic (PK) and subjective response data from 11 clinical abuse potential trials in recreational opioid users following oral and nasal administration of intact and manipulated oxycodone, hydrocodone and morphine products from the FDA internal database were utilized for the present analysis...Our findings support FDA's recommendation of comparative PK studies with early partial AUCs as a supportive PK metric for the assessment of abuse deterrent properties of generic opioid drug products in the general and product-specific guidance's of ADFs. The study was partially funded by Fiscal Year 2017 Critical Path of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.
  • ||||||||||  Hysingla ER (hydrocodone bitartrate) / Purdue
    Abuse and misuse of XTAMPZA® ER relative to other opioid analgesics () -  Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_7;    
    No abuse or misuse of XTAMPZA ER via unintended routes of administration was reported in the Poison Center Program. The proportion of cases involving use via unintended routes of administration was lower for XTAMPZA ER than for comparator drug groups among individuals entering treatment for opioid use disorders.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
    Journal:  Post-Discharge Opioid Use Following Lower Extremity Bypass Surgery. (Pubmed Central) -  Aug 4, 2021   
    Over 60% of pills were unused, which poses significant societal risk for misuse. Our findings contribute to knowledge of operation-specific opioid use, which may shape practice recommendations and reduce opioid overprescription after vascular surgery.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, Nucynta (tapentadol) / Collegium Pharma, Grunenthal
    Retrospective data, Review, Journal:  Efficacy and Safety of Tapentadol Immediate Release for Acute Pain: A Systematic Review and Meta-analysis. (Pubmed Central) -  Jul 28, 2021   
    Tapentadol IR is as effective as other opioids at higher doses for acute pain and is associated with fewer gastrointestinal adverse effects. Based on these findings, tapentadol IR can be considered as a first line opioid for acute pain.
  • ||||||||||  Journal:  Measuring Prescription Opioid Misuse and Its Consequences. (Pubmed Central) -  Jul 28, 2021   
    The rapid expansion of opioid prescribing was accompanied by increasing misuse and mortality. Interventions such as prescription drug monitoring programs (PDMP), increased law enforcement and abuse deterrent formulations have been followed by decreases in misuse of most opioid analgesics.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, Belbuca (buprenorphine BEMA) / BDSI, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
    Journal:  Limited Access to On-Label Formulations of Buprenorphine for Chronic Pain as Compared with Conventional Opioids. (Pubmed Central) -  May 15, 2021   
    By substituting buprenorphine as the firstline treatment for chronic and even acute pain, there may be fewer prescribed conventional opioids in the United States. Schedule III buprenorphine formulations for chronic pain should be given unrestricted access for appropriate patients before considering a Schedule II opioid as a public health priority.
  • ||||||||||  Xtampza ER (oxycodone) / Collegium Pharma
    P4 data, Journal:  Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER. (Pubmed Central) -  May 15, 2021   
    Xtampza ER abuse, misuse, and diversion and tampering are low relative to other prescription opioid analgesics. Abuse and diversion did not increase over the study period.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Dashboard development to identify and track clinical and operational outcomes associated with high-cost/high-utilization medications () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_1871;    
    Medications tested included: sugammadex, vasopressin, pembrolizumab, albumin, everolimus, propofol, acetaminophen, fentanyl, oxycodone immediate-release, and morphine injection...Operations focused variables will include incremental changes in drug expenditure and utilization, compared to internal benchmarks and peer institutions within the network. The dashboard with comparative reporting will be utilized to identify areas where cost savings may occur through changes in utilization or in purchasing practices.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
    Journal:  Managing opioid consumption after caesarean delivery: a quality improvement initiative. (Pubmed Central) -  Sep 9, 2020   
    We should conduct studies to confirm the safety and effectiveness of these opioid practices for cancer dyspnea. The results of this study suggest that postoperative opioid consumption can be reduced with specific analgesic protocols and allow us to improve patient's quality of recovery.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
    Clinical, Journal:  Large Opioid Prescriptions Are Unnecessary After Total Joint Arthroplasty: A Randomized Controlled Trial. (Pubmed Central) -  Jul 31, 2020   
    Tapentadol is a safe and effective analgesic in the treatment of acute postoperative pain. Prescribing fewer OxyIR pills is associated with a significant reduction in unused opioid pills and decreased opioid consumption with no increase in pain scores and no difference in patient-reported outcomes.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, oxycodone controlled release / Generic mfg.
    Review, Journal, HEOR:  Oxycodone versus morphine for cancer pain titration: A systematic review and pharmacoeconomic evaluation. (Pubmed Central) -  Jul 18, 2020   
    Prescribing fewer OxyIR pills is associated with a significant reduction in unused opioid pills and decreased opioid consumption with no increase in pain scores and no difference in patient-reported outcomes. CR oxycodone could be a cost-effective option compared with SR morphine for moderate to severe cancer pain titration in China, according to the threshold defined by the WHO.
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / Allergan, QRxPharma, ibuprofen / Generic mfg.
    Journal:  Continuous local bupivacaine wound infusion with neuraxial morphine reduces opioid consumption after cesarean delivery. (Pubmed Central) -  Feb 9, 2020   
    We found a significant reduction in postoperative opioid use when continuous infusion of bupivacaine for local incisional pain control was added to our standard pain management with neuraxial morphine after cesarean delivery. As a result of this quality improvement initiative, we have implemented this intervention universally as a part of our multimodal postoperative pain management strategy.
  • ||||||||||  Nucynta (tapentadol) / Collegium, Grunenthal
    Journal:  Assessment of Tapentadol API Abuse Liability with the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System. (Pubmed Central) -  Oct 30, 2019   
    Tapentadol (API) was compared with tramadol, hydrocodone, morphine, oxycodone, hydromorphone, and oxymorphone across Poison Center, Drug Diversion, and Treatment Center Programs Combined data streams from the Researched Abuse, Diversion and Addiction-Related Surveillance system...However, when adjusted for drug availability, event rates of abuse were lower than most CII opioids studied, but were not the lowest. Disentangling these two sets of findings further by examining various opioid formulations, such as extended-release and the role of abuse-deterrent formulations, is warranted.
  • ||||||||||  Arymo (morphine) / Egalet
    Journal:  Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration. (Pubmed Central) -  Aug 8, 2019   
    ...CRTs (reformulated oxycodone extended-release [ER], reformulated oxymorphone ER, and tapentadol ER) were compared with non-CRT versions, morphine ER, and oxycodone immediate-release single entity...Results suggest the need for abuse-deterrent formulations designed to reduce abuse by oral administration with product manipulation, such as chewing. Advances in this area may reduce the overall abuse of prescription opioids and interrupt the progression from abuse by swallowing whole to oral administration involving product manipulation and other ROAs.